Educational Programmes

Dr. Tracy L. Stockley

Dr. Stockley is the Head of the Department of Clinical Laboratory Genetics at the University Health Network in Toronto. The Department is the largest molecular pathology laboratory service in Canada and consists of two labs, the translational Advanced Molecular Diagnostics Laboratory at the Princess Margaret Cancer Center, and the clinical Genome Diagnostics Laboratory at Toronto General Hospital. Dr. Stockley’s role at UHN includes oversight of genetic testing for oncology including companion diagnostics, genomic test development for clinical laboratory use, and applications of next-generation sequencing to clinical care. Dr. Stockley has an interest in quality improvement related to high-complexity laboratory testing, and has participated in standard development for molecular diagnostics with multiple national and international organizations including Health Canada, Clinical Laboratory Standards Institute (CLSI), European Molecular Quality Network and the International Organization for Standardization (ISO). Dr. Stockley is an Associate Professor in the Department of Laboratory Medicine and Pathobiology at the University of Toronto, and the current President of the Canadian College of Medical Geneticists.

Relevant Publications

TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses


Mandilaras V, Garg S, Cabanero M, Tan Q, Pastrello C, Burnier J, Karakasis K, Wang L, Dhani NC, Butler MO, Bedard PL, Siu LL, Clarke B, Shaw PA, Stockley T, Jurisica I, Oza AM, Lheureux S
Int. J. Gynecol. Cancer, 2019 — Journal Article
Website Abstract

Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer


Tomasini P, Mascaux C, Jao K, Labbe C, Kamel-Reid S, Stockley T, Hwang DM, Leighl NB, Liu G, Bradbury PA, Pintilie M, Tsao MS, Shepherd FA Clin. Lung Cancer, 2018 — Journal Article
Website Abstract

Somatic Tumor Variant Filtration Strategies to Optimize Tumor-Only Molecular Profiling Using Targeted Next-Generation Sequencing Panels


Sukhai MA, Misyura M, Thomas M, Garg S, Zhang T, Stickle N, Virtanen C, Bedard PL, Siu LL, Smets T, Thijs G, Van Vooren S, Kamel-Reid S, Stockley TL
J. Mol. Diagn., 2018 — Journal Article
Website Abstract

Distinct patterns of clonal evolution in patients with concurrent myelo- and lymphoproliferative neoplasms


Kennedy JA, Medeiros JJF, Dobson SM, Arruda A, Sukhai MA, Stockley T, Tierens A, Minden MD, Kamel-Reid S, Dick JE, Gupta V
Blood, 2018 — Journal Article
Website

Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap


McCuaig JM, Stockley TL, Shaw P, Fung-Kee-Fung M, Altman AD, Bentley J, Bernardini MQ, Cormier B, Hirte H, Kieser K, … (4 more) … , Provencher D, Schrader KA, Serfas K, Tomiak E, Wong N, Young SS, Gotlieb WH, Hoskins P, Kim RH, BRCA TtoT Community of Practice
J. Med. Genet., 2018 — Journal Article
Website Abstract

Additional germline findings from a tumor profiling program


Stjepanovic N, Stockley TL, Bedard PL, McCuaig JM, Aronson M, Holter S, Semotiuk K, Leighl NB, Jang R, Krzyzanowska MK, Oza AM, Gupta A, Elser C, Ahmed L, Wang L, Kamel-Reid S, Siu LL, Kim RH
BMC Med. Genomics, 2018 — Journal Article
Website Abstract

Detection of EGFR mutations in cfDNA and development of resistance


O’Kane GM, Liu G, Stockley T, Shabir M, Zhang T, Le L, Shepherd FA, Bradbury PA, Leighl NB
J. Clin. Orthod., 2018 — Journal Article
Website Abstract

Evidence-based best practices for EGFR T790M testing in lung cancer in Canada


Stockley T, Souza CA, Cheema PK, Melosky B, Kamel-Reid S, Tsao MS, Spatz A, Karsan A
Curr. Oncol., 2018 — Journal Article
Website Abstract

Improving validation methods for molecular diagnostics: application of Bland-Altman, Deming and simple linear regression analyses in assay comparison and evaluation for next-generation sequencing


Misyura M, Sukhai MA, Kulasignam V, Zhang T, Kamel-Reid S, Stockley TL
J. Clin. Pathol., 2017 — Journal Article
Website Abstract

Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies


Thomas M, Sukhai MA, Zhang T, Dolatshahi R, Harbi D, Garg S, Misyura M, Pugh T, Stockley TL, Kamel-Reid S
Arch. Pathol. Lab. Med., 2017 — Journal Article
Website Abstract

Comparison of Next-Generation Sequencing Panels and Platforms for Detection and Verification of Somatic Tumor Variants for Clinical Diagnostics


Misyura M, Zhang T, Sukhai MA, Thomas M, Garg S, Kamel-Reid S, Stockley TL
J. Mol. Diagn., 2016 — Journal Article
Website Abstract

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial


Stockley TL, Oza AM, Berman HK, Leighl NB, Knox JJ, Shepherd FA, Chen EX, Krzyzanowska MK, Dhani N, Joshua AM, … (10 more) … , Wang L, Virtanen C, Kim RH, Razak AR, Hansen AR, Yu C, Pugh TJ, Kamel-Reid S, Siu LL, Bedard PL
Genome Med., 2016 — Journal Article
Website Abstract

Dr. Luca Toschi

Luca Toschi, MD is a Medical Oncologist currently serving at Humanitas Cancer Center in Milan, Italy, where he is involved with patient care and translational research programs in lung cancer.

Dr. Toschi obtained his Medical Degree at University of Bologna and completed his residency in Medical Oncology at the University of Milan. In 2001 and 2002 he served as a short term research intern at the International Agency for Research on Cancer in Lyon, France, where he studied genetic aberrations in oxyphilic thyroid tumors. In 2004 he joined the Cytogenetics Core at Colorado Cancer, Aurora, CO as a research intern to investigate the use of Fluorescent In Situ Hybridization in non-small cell lung cancer (NSCLC) patients treated with Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors. From 2007 to 2010 he served as research fellow at Dana Farber Cancer Institute, Boston, MA in Pasi Jänne laboratory where he focused on the characterization of mechanisms of acquired resistance to EGFR and c-MET inhibitors in NSCLC. Dr. Toschi’s research has been supported by Associazione Italiana perla Ricercasul Cancro and the International Association for the Study of Lung Cancer.

Prof. Fernando López-Ríos

Fernando López-Ríos is Director of Pathology and the Targeted Therapies Laboratory at the Hospital Universitario HM Sanchinarro in Madrid (Spain) and Professor of Pathology and Molecular Pathology at Universidad CEU San Pablo in Madrid. He received his medical degree and PhD in Madrid from the Faculty of Medicine at Autónoma University and Complutense University respectively, and completed his residency in pathology at the University Hospital ‘12 de Octubre’ in Madrid. Dr López-Ríos has also been a visiting researcher at the Memorial Sloan Kettering Cancer Center, New York, USA. His main clinical and research expertise is in cancer biomarker testing with a special emphasis in lung cancer and mesothelioma. He is currently a member of the IASLC pathology committee.

Relevant Publications

López-Ríos F, Illei PB, Rusch V, Ladanyi M. Multiple lines of evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive SV40 PCR results due to presence of SV40 sequences in common laboratory plasmids. Lancet 2004; 364: 1157-1166.

Conde E, Angulo B, Tang M, Morente M, Torres-Lanzas J, López-Encuentra A, López-Ríos F, Sánchez-Céspedes M. Molecular context of the epidermal growth factor receptor mutations: evidence for the activation of mTOR/S6K signalling. Clin Cancer Res 2006; 12: 710-717.

López-Ríos F, Chuai S, Flores R, Shimizu S, Ohno T, Wakahara K, Illei PB, Hussain S, Krug L, Zakowski MF, Rusch V, Olshen AB, Ladanyi M. Global gene expression profiling of pleural mesotheliomas. Overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 2006; 66: 2970-2979.

López-Ríos F, Sánchez-Aragó M, García-García E, Ortega AD, Berrendero JR, Pozo-Rodríguez F, López-Encuentra A, Ballestín C, Cuezva JM. Loss of the mitochondrial bioenergetic capacity underlies the glucose avidity of Carcinomas. Cancer Res 2007; 67: 9013-9017.

Angulo B, Suarez-Gauthier A, López-Ríos F, Medina PP, Conde E, Tang M, Soler G, Lopez-Encuentra A, Cigudosa JC, Sanchez-Cespedes M. Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification. J Pathol 2008; 214: 347-356.

Agulló-Ortuño MT, López-Ríos F, Paz-Ares L. Lung cancer genomic signatures. J Thorac Oncol 2010; 5: 1673-1691.

Thunnissen E, Bubendorf L, Dietel M, Elmberger G, Kerr K, Lopez-Rios F, Moch H, Olszewski W, Pauwels P, Penault-Llorca F, Rossi G. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch 2012; 461: 245-257.

Conde E, Angulo B, Izquierdo E, Muñoz L, Suárez-Gauthier A, Plaza C, Dominguez N, Torres M, Madrigal L, Rubio-Viqueira B, Belda-Iniesta C, Hidalgo M, López-Ríos F. The ALK translocation in advanced non-small-cell lung carcinomas: preapproval testing experience at a single cancer centre. Histopathology 2013; 62: 609-616.

Conde E, Suárez-Gauthier A, Benito A, Garrido P, García-Campelo R, Biscuola M, Paz-Ares L, Hardisson D, de Castro J, Camacho MC, Rodriguez-Abreu D, Abdulkader I, Ramirez J, Reguart N, Salido M, Pijuán L, Arriola E, Sanz J, Folgueras V, Villanueva N, Gómez-Román J, Hidalgo M, López-Ríos F. Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry. PLoS One 2014; 9: e107200.

Bubendorf L, Büttner R, Al-Dayel F, Dietel M, Elmberger G, Kerr K, López-Ríos F, Marchetti A, Öz B, Pauwels P, Penault-Llorca F, Rossi G, Ryška A, Thunnissen E. Testing for ROS1 in non-small cell lung cancer: a review with recommendations. Virchows Arch 2016; 469: 489-503.

Kerr KM, López-Ríos F. Precision medicine in NSCLC and pathology: how does ALK fit in the pathway? Ann Oncol. 2016: Suppl 3:iii16-iii24.

Büttner R, Gosney JR, Skov BG, Adam J, Motoi N, Bloom KJ, Dietel M, Longshore JW, López-Ríos F, Penault-Llorca F, Viale G, Wotherspoon AC, Kerr KM, Tsao MS. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer. J Clin Oncol 2017; 35: 3867-3876.

Conde E, Caminoa A, Dominguez C, Calles A, Walter S, Angulo B, Sánchez E, Alonso M, Jimenez L, Madrigal L, Hernando F, Sanz-Ortega J, Jimenez B, Garrido P, Paz-Ares L, de Castro J, Hernandez S, Lopez-Rios F. Aligning digital CD8(+) scoring and targeted next-generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early-stage squamous cell lung carcinoma. Histopathology 2018; 72: 270-284.

Yatabe Y, Dacic S, Borczuk AC, Warth A, Russell PA, Lantuejoul S, Beasley MB, Thunnissen E, Pelosi G, Rekhtman N, Bubendorf L, Mino-Kenudson M, Yoshida A, Geisinger KR, Noguchi M, Chirieac LR, Bolting J, Chung JH, Chou TY, Chen G, Poleri C, Lopez-Rios F, Papotti M, Sholl LM, Roden AC, Travis WD, Hirsch FR, Kerr KM, Tsao MS, Nicholson AG, Wistuba I, Moreira AL. Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. J Thorac Oncol 2019; 14: 377-407.

Büttner R, Longshore JW, López-Ríos F, Merkelbach-Bruse S, Normanno N, Rouleau E, Penault-Llorca F. Implementing TMB measurement in clinical practice: considerations on assay requirements. ESMO Open 2019; 4: e000442.

Prof. Ezra Cohen

Ezra Cohen, MD, is co‐Director of the San Diego Center for Precision Immunotherapy and an internationally renowned translational researcher. A physician‐scientist, Dr. Cohen led an independently funded laboratory interested in mechanisms of action of novel therapeutics. He has made major contributions to targeted and immunotherapy. His research has received peer-reviewed funding in the study of epidermal growth factor receptor inhibitors, cell therapy, and immunotherapy in head and neck cancer. He has made major contributions to the understanding of critical signaling pathways, integration of novel agents into standard of care, and definition of mechanisms to overcome resistance to drug therapy. He has also recently co‐developed a personalized neoantigen vaccine using unique cancer mutations to boost an anti‐tumor immune response.

Dr. Cohen is Associate Director for Translational Science and leader of the Solid Tumor Therapeutics research program at Moores Cancer Center. He brings his expertise and preeminent reputation in head and neck cancer research and patient care to solid tumor therapeutics. Among other roles, he is chair of the Protocol Review and Monitoring Committee (PRMC) and serves as a member of the Cancer Council, and the Cancer Center’s Executive Committee.
Dr. Cohen recently served as editor‐in‐chief of Oral Oncology, the highest impact specialty journal in head and neck cancer, and currently serves as senior editor for Clinical Cancer Research. He has been the principal investigator on multiple studies of novel agents in head and neck cancer and other solid tumors in all phases of development including chemoprevention, phase I, II, and III trials. Dr. Cohen has authored more than 170 papers and has presented his research at national and international meetings. In addition, he has served as a grant reviewer for the NIH, American Association for Cancer Research, American Society of Clinical Oncology, and the Ontario Institute for Cancer Research.

Dr. Cohen completed residencies in Family Medicine at the University of Toronto and in Internal Medicine at Albert Einstein College of Medicine. He completed a Hematology/Oncology fellowship at the University of Chicago where he was named chief fellow. Prior to his arrival in San Diego, Dr. Cohen was Co‐Director of the Head and Neck Cancer Program, Associate Director for Education and Program Director for the Hematology/Oncology Fellowship at the University of Chicago Comprehensive Cancer Center. A dedicated educator, Dr. Cohen also mentored and developed young faculty in his program.

Prof. Andrea Sartore-Bianchi

Relevant Publications

Mauri G, Valtorta E, Cerea G, Amatu A, Schirru M, Marrapese G, Fiorillo V,
Recchimuzzo P, Cavenago IS, Bonazzina EF, Motta V, Lauricella C, Veronese S, Tosi
F, Maiolani M, Rospo G, Truini M, Bonoldi E, Christiansen J, Potts SJ, Siena S,
Sartore-Bianchi A. TRKA expression and NTRK1 gene copy number across solid
tumours. J Clin Pathol. 2018 Oct;71(10):926-931. doi:
10.1136/jclinpath-2018-205124. Epub 2018 May 25. PubMed PMID: 29802225.

Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Tejpar S,
Sartore-Bianchi A, Hechtman JF, Christiansen J, Novara L, Tebbutt N, Fucà G,
Antoniotti C, Kim ST, Murphy D, Berenato R, Morano F, Sun J, Min B, Stephens PJ,
Chen M, Lazzari L, Miller VA, Shoemaker R, Amatu A, Milione M, Ross JS, Siena S,
Bardelli A, Ali SM, Falcone A, de Braud F, Cremolini C. ALK, ROS1, and NTRK
Rearrangements in Metastatic Colorectal Cancer. J Natl Cancer Inst. 2017 Dec
1;109(12). doi: 10.1093/jnci/djx089. PubMed PMID: 29370427.

Sartore-Bianchi A, Amatu A, Bonazzina E, Stabile S, Giannetta L, Cerea G,
Schiavetto I, Bencardino K, Funaioli C, Ricotta R, Cipani T, Schirru M, Gambi V,
Palmeri L, Carlo-Stella G, Rusconi F, Di Bella S, Burrafato G, Cassingena A,
Valtorta E, Lauricella C, Pazzi F, Gambaro A, Ghezzi S, Marrapese G, Tarenzi E,
Veronese S, Truini M, Vanzulli A, Siena S. Pooled Analysis of Clinical Outcome of
Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase
I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A
Single-Institution Experience. Target Oncol. 2017 Aug;12(4):525-533. doi:
10.1007/s11523-017-0505-6. PubMed PMID: 28669023; PubMed Central PMCID:
PMC5524857.

Siravegna G, Sartore-Bianchi A, Mussolin B, Cassingena A, Amatu A, Novara L,
Buscarino M, Corti G, Crisafulli G, Bartolini A, Tosi F, Erlander M, Di
Nicolantonio F, Siena S, Bardelli A. Tracking a CAD-ALK gene rearrangement in
urine and blood of a colorectal cancer patient treated with an ALK inhibitor. Ann
Oncol. 2017 Jun 1;28(6):1302-1308. doi: 10.1093/annonc/mdx095. PubMed PMID:
28368455.

Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler
JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A,
Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca
M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D,
Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG. Safety and Antitumor
Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib:
Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer
Discov. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb
9. PubMed PMID: 28183697; PubMed Central PMCID: PMC5380583.

Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of
cancer therapy across multiple tumour types. ESMO Open. 2016 Mar 18;1(2):e000023.
eCollection 2016. Review. PubMed PMID: 27843590; PubMed Central PMCID:
PMC5070277.

Amatu A, Somaschini A, Cerea G, Bosotti R, Valtorta E, Buonandi P, Marrapese
G, Veronese S, Luo D, Hornby Z, Multani P, Murphy D, Shoemaker R, Lauricella C,
Giannetta L, Maiolani M, Vanzulli A, Ardini E, Galvani A, Isacchi A,
Sartore-Bianchi A, Siena S. Novel CAD-ALK gene rearrangement is drugable by
entrectinib in colorectal cancer. Br J Cancer. 2015 Dec 22;113(12):1730-4. doi:
10.1038/bjc.2015.401. Epub 2015 Dec 3. PubMed PMID: 26633560; PubMed Central
PMCID: PMC4701996.

Sartore-Bianchi A, Ardini E, Bosotti R, Amatu A, Valtorta E, Somaschini A,
Raddrizzani L, Palmeri L, Banfi P, Bonazzina E, Misale S, Marrapese G, Leone A,
Alzani R, Luo D, Hornby Z, Lim J, Veronese S, Vanzulli A, Bardelli A, Martignoni
M, Davite C, Galvani A, Isacchi A, Siena S. Sensitivity to Entrectinib Associated
With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer. J Natl
Cancer Inst. 2015 Nov 12;108(1). pii: djv306. doi: 10.1093/jnci/djv306. Print
2016 Jan. PubMed PMID: 26563355; PubMed Central PMCID: PMC4712682.

Medico E, Russo M, Picco G, Cancelliere C, Valtorta E, Corti G, Buscarino M,
Isella C, Lamba S, Martinoglio B, Veronese S, Siena S, Sartore-Bianchi A, Beccuti
M, Mottolese M, Linnebacher M, Cordero F, Di Nicolantonio F, Bardelli A. The
molecular landscape of colorectal cancer cell lines unveils clinically actionable
kinase targets. Nat Commun. 2015 Apr 30;6:7002. doi: 10.1038/ncomms8002. PubMed
PMID: 25926053.

Ardini E, Bosotti R, Borgia AL, De Ponti C, Somaschini A, Cammarota R,
Amboldi N, Raddrizzani L, Milani A, Magnaghi P, Ballinari D, Casero D, Gasparri
F, Banfi P, Avanzi N, Saccardo MB, Alzani R, Bandiera T, Felder E, Donati D,
Pesenti E, Sartore-Bianchi A, Gambacorta M, Pierotti MA, Siena S, Veronese S,
Galvani A, Isacchi A. The TPM3-NTRK1 rearrangement is a recurring event in
colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase
inhibition. Mol Oncol. 2014 Dec;8(8):1495-507. doi: 10.1016/j.molonc.2014.06.001.
Epub 2014 Jun 12. PubMed PMID: 24962792; PubMed Central PMCID: PMC5528583.

Prof. Viktor Grünwald, MD

Viktor Grünwald is a professor for Interdisciplinary Urooncology at the University Hospital Essen. Professor Grünwald specialises in Internal Medicine and Medical Oncology. His main areas of research interest are in renal cell carcinoma, soft tissue sarcomas, head and neck cancers, with an emphasis on the development of molecular and immunotherapies.

Prof Grünwald graduated from the Medical School Hannover in 1998, after which he was appointed as a Private Lecturer in Haematology and Oncology at the same institution. He became professor for Haematology and Oncology at the Medical School Hannover in 2014. Professor Grünwald was appointed to the steering committee for genitourinary (GU) cancers (non-prostate) at the ESMO and ESMO ASIA Congress and is part of scientific committees of the International Kidney Cancer Symposium (EIKCS), German Cancer Congress (DKK) and the German Society for Hematology and Oncology (DGHO). He has co-chaired the Phase 3 Working Group of the Central European Society of Anticancer Drug Research (CESAR) studies group and a former member of the board of the German Medical Oncology studies group (AIO). Prof. Grünwald chairs the AIO Head and Neck (SCCHN) Working Group and within the AIO he is the former spokesman of the Sarcoma (STS) Working Group. Within the German Cancer Society, he chairs the Working Group for renal tumors (RCC) and is co-chair of the interdisciplinary head and neck tumors group. He chairs the ESMO preceptorship on SCCHN and is part of the faculty of the ECCO-AACR-EORTC-ESMO workshop on methods in clinical cancer research. His current trial proposals explore novel concepts in RCC, STS and SCCHN, focusing on translational research and drug development of immunotherapies in these indications.

Relevant Publications

Escudier, B. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 1–43 (2019). doi:10.1093/annonc/mdz056

PhD, P. D. C. et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncology 1–14 (2019). doi:10.1016/S1470-2045(18)30778-2

Grünwald, V. et al. An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma. Nat Rev Urol 93, 1237 (2018).

Schöffski, P. et al. Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’. Annals of Oncology (2018). doi:10.1093/annonc/mdx823

Casali, P. G. et al. Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels. Journal of Clinical Oncology 35, 1713–1720 (2017).

Prof. Frédéric Bibeau

Frédéric Bibeau, MD, PhD, is a Professor of Pathology at the head of the Pathology Department of the Caen University Hospital, Normandy University. He is involved translational research, in immunoncology of solid tumors and in gastrointestinal tumor pathology, notably colorectal cancer, both at the diagnostic and research levels. For ten years his work has been focused on rectal cancer, microsatellite instable colorectal cancer, liver metastases after induction treatment, peritoneal carcinomatosis and predictive factors linked to targeted therapies and immunotherapy. He also involved national and international groups specialized in rare tumors of the peritoneum. He is one of two coordinators of the BIG-RENAPE network, corresponding to a biological and clinical database dedicated to peritoneal carcinomatosis of digestive origin.
Professor Bibeau is author or co-author of 179 publications. He belongs to the board of national and international reviews. He is a member of the French Society of Pathology, International Academy of Pathology and the European Society of Medical Oncology.

CATERINA MARCHIÒ, MD PhD

Caterina Marchiò, MD PhD, obtained her medical degree at The University of Turin graduating summa cum laude in 2004. She completed her PhD in 2008 after working in collaboration between the University of Turin and the Breakthrough Breast Cancer Research Centre at the Institute of Cancer Research in London between 2006 and 2008. Upon completion of the residency in Pathology at the University of Turin she visited as a Research Scholar the Department of Pathology at Memorial Sloan Kettering Cancer Centre in New York in 2014.

She joined the faculty at the University of Turin as an Assistant Professor of pathology at the end of 2014 and she was appointed Associate Professor of Pathology in 2018. Between 2017 and 2018 she served as Visiting Professor at the Pathology Department of Institut Curie in Paris, as a Mayent-Rotschild grantee.

Prof. Caterina Marchiò is a diagnostic and experimental pathologist at the Pathology Unit of FPO-IRCCS Candiolo Cancer Institute (University of Turin). Her routine diagnostic activity focuses on breast pathology and molecular diagnostics of solid tumors, including sign-out for in situ hybridization, DNA sequencing and RNA-based assays applied to diagnostics. Her research interests span from histopathogenesis of breast carcinomas to molecular pathology of special histologic types of breast cancer and genetics of HER2-positive carcinomas. A specific interest in HER2-equivocal breast cancer has been funded by the Italian Association of Cancer Research (AIRC), Regione Piemonte and the Ministry of University, Education and Research. She has also actively worked on the standardization of the preanalytical conditions in Pathology to ensure optimal tissue preservation and quality of DNA, RNA and antigens. She is part of the SPIDIA4P consortium, funded by the European Community (H2020-SC1-2016-2017, EU project 733112 – “SPIDIA4P – SPIDIA for Personalized Medicine).

Dr. Erin Rudzinski

Dr. Erin Rudzinski completed her undergraduate degree at Berry College, graduating magna cum laude in 1999. She obtained her medical degree from the Medical College of Georgia in 2003. Dr. Rudzinski completed her anatomic and clinical pathology residency at Vanderbilt University Medical Center in 2007. Following her residency, she completed an additional anatomic pathology fellowship year at Vanderbilt, followed by a pediatric pathology fellowship at Seattle Children’s Hospital/University of Washington Medical Center. She joined the staff at Seattle Children’s Hospital in 2009, and she is currently a Clinical Associate Professor in the Department of Pathology at the University of Washington.

Dr. Rudzinski specializes in pediatric solid tumors, with a focus on pediatric soft tissue tumors. The goal of her research is improving the morphologic and molecular classification of pediatric soft tissue tumors, including the development of ancillary diagnostic biomarkers (ie. immunohistochemistry). Dr. Rudzinski is an active member of the Children’s Oncology Group, the College of American Pathologists, and the Society for Pediatric Pathology.

Relevant Publications

Patel S, Rudzinski ER, Perkins J. Congenital neurocristic tumor of the head and neck. The Laryngoscope, 2013 Mar;123(3):805-8.

Skapek SX, Hawkins DS, Anderson J, Barr FG, Bridge J, Gastier-Foster JM, Parham DM, Rudzinski ER, Triche T. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A Children’s Oncology Group report. Pediatric Blood and Cancer. 2013 Sep;60(9):1411-7.

Rudzinski ER, Teot LA, Anderson JR, Moore JA, Bridge JA, Barr FG, Gastier-Foster JM, Skapek SX, Hawkins DS, Parham DM. The dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. American Journal of Clinical Pathology. 2013, Jul;140(1):82-90.

Rudzinski ER, Anderson JR, Lyden ER et al. Myogenin, AP2β, NOS-1 and HMGA2 are surrogate markers of fusion status in rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. American Journal of Surgical Pathology. 2014, May;38(5):654-659.

Rudzinski ER, Anderson JR, Hawkins DH et al. The World Health Organization classification of skeletal muscle tumors in pediatric rhabdomyosarcoma: A report from the Children’s Oncology Group. Archives of Pathology and Laboratory Medicine. 2015;139(10):1281-7.

Arnold MA, Anderson JR, Gastier-Foster JM, Barr FG, Skapek SX, Hawkins DS, Raney RB, Parham DM, Teot LA, Rudzinski ER and Walterhouse DO. Histology, Fusion Status and Outcome in Alveolar Rhabdomyosarcoma with Low-Risk Clinical Features: A Report from the Children’s Oncology Group. Pediatric Blood and Cancer. 2016;63(4):634-9.

Siegele B, Roberts J, Black JO, Rudzinski ER, Vargas SO, Galambos C. DUX4 Immunohistochemistry is a highly sensitive and specific marker for CIC-DUX4 fusion-positive round cell tumor. Am J Surg Pathol 2017;41(3):423-429.

Pinto N, Park JR, Murphy E, Yearley J, McClanahan T, Annamalai L, Hawkins DS, Rudzinski ER. Patterns of PD-1, PDL-1 and PDL-2 expression in pediatric solid tumors. Pediatric Blood and Cancer 2017 64(11)

Rudzinski ER, Anderson JR, Ch YY, et al. Histology, fusion status and outcome in metastatic rhabdomyosarcoma: a report from the Children’s Oncology Group. Pediatric Blood and Cancer 2017 64(12)

Davis JL, Lockwood CM, Tsuchiya K, Albert C, Hawkins DS, Rudzinski ER. Infantile NTRK-associated mesenchymal tumors. Pediatric and Developmental Pathology. 2018 21(1):68-78.

Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma P, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku N, Cox MC, Hawkins DS, Hong DS, Hyman DM. Efficacy of Larotrectinib in TRK fusion-positive adult and pediatric cancers. New England Journal of Medicine 2018 Feb 22;387(8):731-739.

Laetsch TW, Dubois SG, Turpin B, Federman N, Mascarenhas L, Albert CM, Nagasubramanian R, Davis JL, Rudzinski ER, Feraco A, Tuch BB, Ebata KT, Reynods M, Smith S, Cruickshank S, Cox MC, Pappo AS, Hawkins DS. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: a multicenter, open-label, phase 1 study. Lancet Oncology. 2018;19(5):705-714.

Rudzinski ER, Lockwood CM, Stohr BA, Vargas SO, Sheridan R, Black JO, Rajaram V, Laetsch TW, Davis JL. Pan-Trk immunohistochemistry identifies NTRK rearrangements in pediatric mesenchymal tumors. Am J Surg Pathol 2018;42(7):927-935.

Hawkins DS, Chi YY, Anderson JR, Tian J, Arndt CAS, Bomgaars L, Donaldson SS, Hayes-Jordan A, Mascarenhas L, McCarville MB, McCune JS, McCowage G, Million L, Morris CD, Parham DM, Rodeberg DA, Rudzinski ER, Shnorhavorian M, Spunt SL, Skapek SX, Teot LA, Wolden S, Yock TI, Meyer WH. Addition of vincristine and irinotecan (VI) to vincristine, dactinomycin and cyclophosphamide (VAC) does not improve outcome for intermediate-risk rhabdomyosarcoma: a report from the Children’s Oncology Group. Journal of Clinical Oncology 2018;36(27):2770-2777.

Davis JL, Lockwood DM, Stohr B, Boecking C, Al-Ibraheemi A, DuBois SG, Vargas SO, Black JO, Cox MC, Luquette M, Turpin B, Szabo S, Laetsch TW, Albert CM, Parham DM, Hawkins DS, Rudzinski ER. Expanding the spectrum of pediatric NTRK-rearranged mesenchymal tumors. Am J Surg Pathol, epub ahead of print, Dec 24 2018.